US growth now mainly dependant on new launches US generics comprise 35% of total revenues and have grown at a CAGR of ~14% in FY13-18. So far, the company has received approvals for 139 ANDAs while another 61 are pending approval, of which 29 are Para IV applications. Key therapies in the US, going forward, will be oncology dermatology and respiratory. The company expects to launch ~12 products. We expect US to grow at 7.4% CAGR in FY18-20E to | 3703 crore on the back of new launches....